Germ line polymorphisms as predictive markers for pre-surgical radiochemotherapy in locally advanced rectal cancer: a 5-year literature update and critical review.
OBJECTIVE
Locally advanced rectal cancer is currently treated with pre-surgical radiotherapy and chemotherapy. Approximately one-half of patients obtain a relevant shrinkage/disappearance of tumour, with major clinical advantages. The remaining patients, in contrast, show no benefit and possibly need alternative treatment. To provide the best therapeutic option for each individual patient, predictive markers have been widely researched. This review was undertaken to evaluate recent progress made in this field.


METHODS
A systematic literature search was performed using PubMed and Scopus database, focused on germ line gene polymorphisms as biomarkers and response and toxicity as outcomes. Because an exhaustive previous review was available describing findings up to 2008, we restricted our analysis to the last 5 years.


RESULTS
Ten original research articles were found, reporting promising results for some candidate genes in drug metabolism (TYMS, MTHFR), DNA repair (XRCC1, OGG1, CCND1) and inflammation (SOD2, TGFB1)/immunity (IL13) pathways, but with no firm conclusion. All the studies had small sample size and were defined as exploratory. This review highlights pivotal molecular, clinical, genetic and statistical issues in the investigation of genetic polymorphisms as outcome predictors for rectal cancer and offers suggestions for future development.


CONCLUSIONS
What emerges is a clear need for new proposals, especially in view of the increasing evidence for tumour-host and gene-gene interactions during anticancer treatment, together with stronger adherence to proper methodological requirements.
Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Largo Meneghetti, 2, 35131, Padua, Italy, e.pezzolo@gmail.com.
Elisa
E
Pezzolo
Yasmina
Y
Modena
Barbara
B
Corso
Pietro
P
Giusti
Milena
M
Gusella
D014408:Biomarkers, Tumor / Q000235:genetics*; D059186:Chemoradiotherapy, Adjuvant; D004249:DNA Damage / Q000235:genetics; D004260:DNA Repair / Q000235:genetics; D018095:Germ-Line Mutation; D006801:Humans; D020360:Neoadjuvant Therapy; D020641:Polymorphism, Single Nucleotide; D011237:Predictive Value of Tests; D012004:Rectal Neoplasms / Q000235:genetics* / Q000628:therapy*
D014408:Biomarkers, Tumor